泰凌微(688591.SH):2024年淨利潤9,741.03萬元,同比增長95.71%
格隆匯4月17日丨泰凌微(688591.SH)公佈2024年年度報告,2024年,泰凌微在技術創新與市場開拓的雙輪驅動下,交出了一份亮眼的成績單。公司全年實現營業收入84,403.30萬元,同比增長32.69%;實現歸母淨利潤9,741.03萬元,同比增長95.71%;實現扣非歸母淨利潤9,083.34萬元,同比增長296.55%;此外全年公司的毛利率爲48.34%,較上年提高4.84個百分點。總體來看,公司經營業績實現突破性增長,盈利能力顯著增強,展現出強勁的發展韌性和高質量增長態勢。擬向全體股東每10股派發現金紅利2.05元(含稅)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.